Clinical Efficacy and Mechanism of Shengmai Jiuxin Decoction in Treating Chronic Heart Failure with Qi and Yin Deficiency， Yang Deficiency， and Blood Stasis
10.13422/j.cnki.syfjx.20251791
- VernacularTitle:生脉救心汤治疗气阴两虚阳虚血瘀型慢性心力衰竭的临床疗效和机制
- Author:
Yiming YAO
1
;
Hongjun ZHU
2
;
Yang ZHAO
1
;
Man SHI
1
;
Yujin GONG
1
;
Yuan WANG
1
Author Information
1. Nanjing University of Chinese Medicine，Nanjing 210023，China
2. Wuxi Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine，Wuxi 214000，China
- Publication Type:Journal Article
- Keywords:
Shengmai Jiuxin decoction;
acute decompensated heart failure;
Qi and Yin deficiency， Yang deficiency， and blood stasis type;
hypoxia-inducible factor-1 （HIF-1） signaling pathway
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(17):151-158
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical efficacy and potential mechanism of Shengmai Jiuxin decoction in the treatment of acute decompensated heart failure （ADHF） with the traditional Chinese medicine （TCM） pattern of Qi and Yin deficiency， Yang deficiency， and blood stasis. MethodsA total of 68 patients diagnosed with ADHF of Qi and Yin deficiency， Yang deficiency， and blood stasis type were randomly assigned to an observation group （34 cases） and a control group （34 cases）. Both groups received conventional Western medical treatment， while the observation group was additionally administered Shengmai Jiuxin decoction. Parameters compared before and after treatment included： TCM syndrome score， TCM syndrome efficacy， New York Heart Association （NYHA） functional classification， left ventricular ejection fraction （LVEF）， N-terminal pro-B-type natriuretic peptide （NT-proBNP）， six-minute walk distance （6MWD）， hypoxia-inducible factor-1 alpha （HIF-1α）， vascular endothelial growth factor A （VEGF-A）， Caspase-3， and the number of rehospitalizations for heart failure within one month after discharge. ResultsThere were no significant differences in sex， age， vital signs， or underlying diseases between the two groups. Compared with baseline， both groups exhibited significant reductions in TCM syndrome scores， NT-proBNP， and HIF-1α levels （P<0.01）， as well as significant increases in 6MWD， LVEF， VEGF-A， and Caspase-3 levels （P<0.05， P<0.01）. After treatment， the observation group showed significantly greater reductions in TCM syndrome score， NT-proBNP， HIF-1α， and Caspase-3 levels compared with the control group （P<0.05） and significantly greater increases in 6MWD， TCM syndrome efficacy， and VEGF-A levels （P<0.05）. No significant differences were observed between the groups in NYHA functional classification， LVEF， or the number of rehospitalizations for heart failure within one month after discharge. No drug-related adverse events were reported in either group during the treatment period. ConclusionShengmai Jiuxin decoction can improve cardiac function and clinical symptoms in patients with ADHF of Qi and Yin deficiency， Yang deficiency， and blood stasis type. Its mechanisms may be related to the regulation of the HIF-1 signaling pathway by modulating targets such as HIF-1α， VEGF-A， and Caspase-3.
